Today we announced the close of our oversubscribed $80 million Series C financing co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. We also announced the first participant dosed with FMC-376, the first therapeutic candidate discovered with the Frontier™ Platform. Learn more here: https://lnkd.in/esgxPc7X #biotech, #precisionmedicines, #oncology
Frontier Medicines
Biotechnology Research
South San Francisco, CA 16,645 followers
Frontier Medicines is a biopharmaceutical company that “drugs the undruggable” to transform patients’ lives.
About us
Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.
- Website
-
https://frontiermeds.com/
External link for Frontier Medicines
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, CA
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
South San Francisco, CA 94080, US
-
Get directions
451 D Street, Suite 207
Boston, MA 02210, US
Employees at Frontier Medicines
Updates
-
Frontier Medicines reposted this
I'm looking forward to joining such an esteemed panel of my fellow (scrappy) biotech colleagues at the upcoming Fierce Pharma PR & Communications Summit. Hope to see you there! https://lnkd.in/djus9hkp #biotech
-
-
ICYMI: Thanks Sally Church for diving deep into our FMC-376 data at #AACR24 in a conversation with our CSO Kevin Webster #biotech
Executive Editor & Producer at Blue Ice Publishing: Scientist, Adventurer, Explorer of cool things in cancer research
Kicking KRAS to the kerb It's not so long ago when we saw numerous companies vying to to drug targets such as VEGF and EGFR – with limited success in many cases. Even today there are not too many approved drugs in these two categories relative to the number of agents which ended up in 'dog drug heaven'. The dreaded phrase was originally coined by Dr Pat LoRosso while at Karmanos Cancer Centre in Detroit; she's now at Yale and the incoming AACR President. Befitting the lady's style – she's one of the nicest and kindest oncologists I've ever met – it seems a much more pleasant way to describe abandoned or discontinued anticancer agents than referring to the veritable dustbin of failed dreams. The latest posse of drugs needing some stringent culling or shakeout will likely come from the KRAS niche because the market is unlikely to be forgiving commercially of any drug not moving the needle in a substantial fashion. The good news is there are some gems in the rough for those who care to look more carefully and closely at what's needed to move forward. One of them is the focus of our latest company interview from AACR – what are Frontier Medicines doing differently and why does it matter? In an interview with their CSO, Dr Kevin Webster, we learn more about their innovative approach to tackling KRAS G12C... Check it out! https://bit.ly/49AXKGn
-
Join us later today at the #BioITExpo as two of our scientific leaders, Johannes Hermann, PhD and Han Wool Yoon, discuss our work to unite AI and quantum mechanics to unlock a successful future of deliberately designed precision medicines. We believe the answer is yes.
-
-
We presented new preclinical data on our KRASG12C inhibitor, FMC-376, at #AACR24 yesterday. These results demonstrate FMC-376's broad activity regardless of resistance mechanism. #biotech #precisiononcology https://lnkd.in/eCHawQVg
-
-
Thanks Brad Loncar and BiotechTV for taking the time to talk to our co-founder and CEO, Chris Varma about our pipeline and what's next on the horizon for Frontier powered by our platform.
𝐅𝐫𝐨𝐦 𝐁𝐨𝐬𝐭𝐨𝐧: Frontier Medicines is trying to leverage its platform to improve on KRAS G12C by hitting both the on an off forms of the target. The Co-Founder Chris Varma describes why, and discusses a recent $80M series C financing. Full video: https://lnkd.in/g-F8wHEu BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Frontier Medicines reposted this
#Chemoproteomics specialist Frontier Medicines said it closed an oversubscribed $80-million series C to advance the company's lead programme, FMC-376, a first-in-class dual inhibitor of the notoriously difficult-to-drug KRAS oncogene. https://lnkd.in/dcmTsncK #biopharma #biotechnology #clinicalresearch #FrontierMedicines #pharmaceuticals
Frontier's dual KRAS inhibitor enters clinic with $80M boost
ml.firstwordpharma.com
-
Frontier Medicines reposted this
Congratulations to Frontier Medicines on their continued progress – today announcing their first patient dosed with FMC-376 alongside their Series C financing which will support the advancement of multiple programs into clinical studies!
Today we announced the close of our oversubscribed $80 million Series C financing co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. We also announced the first participant dosed with FMC-376, the first therapeutic candidate discovered with the Frontier™ Platform. Learn more here: https://lnkd.in/esgxPc7X #biotech, #precisionmedicines, #oncology
-
-
Frontier Medicines reposted this
It was a big day for Frontier Medicines: $80 million in new funding to advance multiple pipeline programs into clinical studies AND the first participant dosed with a therapeutic candidate born from the Frontier Platform! We're proud to continue backing this impressive team as it works to deliver transformational medicines for patients in need. Congrats, Frontier! 🍾 🎉
Today we announced the close of our oversubscribed $80 million Series C financing co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. We also announced the first participant dosed with FMC-376, the first therapeutic candidate discovered with the Frontier™ Platform. Learn more here: https://lnkd.in/esgxPc7X #biotech, #precisionmedicines, #oncology
-